NCT04943458

Brief Summary

Postoperative cognitive dysfunction (POCD) and delirium (incidence up to 42 %) after cardiac surgery with cardiopulmonary bypass (CPB) are common postoperative complications that impair the patient's quality of life and increase the risk of death. Our previous studies confirm that postoperative POCD are associated with impaired cerebral autoregulation (CA) and momentary increased intracranial pressure (ICP) during surgery. The upper and lower limits of CA are individual and variable. In the elderly, CA is already partially impaired due to decreased cerebral vascular elasticity. What should be the optimal mean arterial pressure for each of these patients individually is not known. In order to individualize the boundaries of CA and prevent postoperative neurological complications, it would be ideal to objectify the condition of cerebral blood vessels. Direct studies of cerebrovascular and vascular status (CT angiography) are invasive and complex, and are therefore not routinely performed prior to cardiac surgery. However, cerebral blood flow and vascular condition can be assessed by retinal blood vessels, which can be considered as a direct biomarker of cerebrovascular disorders and can be visualized by ophthalmoscopy and objectively assessed by optical coherent tomography with angiography. In this biomedical study, individual patient CA will be monitored in a non-invasive manner during cardiac surgery with CPB. These data would allow real-time adjustments to physiological parameters while keeping them within normal limits. This is expected to reduce the risk of CA impairment and reduce the incidence of neurological complications following such surgery. Glaucoma is one of the leading causes of irreversible blindness in the world. As the population ages, the number of people with glaucoma increases as the prevalence of glaucoma increases with age. Recently, the influence of ICP on glaucoma optic neuropathy has been highlighted. It is thought that the pressure difference in the optic nerve area may be related to damage to the axons of the ganglion cells passing through the porous plate. Noninvasive ICP measurement is useful in explaining the pathophysiology of glaucoma, assessing translaminar pressure differentials, and seeking new guidelines for the treatment and prevention of glaucoma. Retinal blood flow, like cerebral blood flow, is autoregulated, autoregulation is maintained only within certain limits of perfusion pressure. Decreased ocular perfusion pressure impairs retinal autoregulation and may lead to the development or progression of glaucoma neuropathy. And the activity of neurons in the brain and retina causes local changes in blood circulation. Disruption of this neurovascular interaction during glaucoma neuropathy has not been adequately studied.The introduction of modern technologies into clinical practice enables the qualitative and quantitative assessment of autoregulatory disorders and the selection of optimal treatment.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
270

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 21, 2021

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 29, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

September 1, 2021

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2022

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2022

Completed
Last Updated

April 5, 2022

Status Verified

April 1, 2022

Enrollment Period

10 months

First QC Date

June 21, 2021

Last Update Submit

April 4, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Impaired cerebral autoregulation and glaucoma neuropathy

    Duration of the longest episode of CA disorder (threshold VRx\> 0, threshold VRx\> 0.2, threshold VRx\> 0.4) showing impaired CA and the changes in vascular density ( %) of OCT-A macular temporal sector assessing the course of glaucoma neuropathy.

    1 days

Secondary Outcomes (1)

  • POCD and glaucoma neuropathy

    5 days up to 1 month

Study Arms (3)

Cardiac surgery group

Other: Monitoring of cerebral autoregulation

Glaucoma group

Other: Monitoring of cerebral autoregulation

Control group

Other: Monitoring of cerebral autoregulation

Interventions

Patients will be monitored for cerebral autoregulation using a Vittamed 505 monitor to identify the dynamics of the autoregulation index VRx (t). Intracranial pressure (ICP) will also be measured by non-invasive ultrasound using a robotic TCD device, Dolphin4D (Israel), which simultaneously records MCA blood flow in both hemispheres of the brain. APAs will be assessed using mathematical models.

Also known as: Non invasive ICP monitoring
Cardiac surgery groupControl groupGlaucoma group

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study will include patients treated at the Clinic of Eye Diseases, Hospital of Lithuanian UHS and patients undergoing elective cardiac surgery (coronary artery bypass graft surgery) at the Clinic of Cardiovascular and Thoracic Surgery, Hospital of Lithuanian UHS.

You may qualify if:

  • Age 18-90 years.
  • The patient, after reading the personal information form, confirms in writing his / her consent to participate in the study.
  • An AVJS operation is planned.
  • No ophthalmological or neurological disorders have been identified prior to surgery.
  • Age 18-90 years.
  • The patient, after reading the personal information form, confirms in writing his / her consent to participate in the study.
  • Patients with glaucoma changes in the optic disc and eye area shall be included in the study group.
  • The control group shall include volunteers who are free from glaucoma, acute or chronic uncompensated disease that may affect the results of the studies, and age and anthropometric data from other study groups.

You may not qualify if:

  • No written consent of a person to participate in a biomedical research has been obtained;
  • Persons under 18 years of age.
  • A woman who may become pregnant, be pregnant or breastfeeding.
  • The patient is allergic or sensitive to local anesthetics.
  • Patients with an eye disease that may distort the results of the test, if so decided by the researcher.
  • The patient had an orbital or eye injury.
  • Has an acute or chronic but currently exacerbated respiratory disease.
  • Patients with uncompensated cardiovascular diseases (II-III AV block or cardiogenic shock).
  • Diabetes mellitus treated with more than one hypoglycaemic agent and / or insulin injections.
  • Cognitive impairment diagnosed before surgery
  • History of neurological diseases
  • It is not possible to perform a qualitative neuropsychological examination due to other reasons (hearing, vision, etc. disorders)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Milda Svagzdiene

Kaunas, Lithuania

RECRUITING

MeSH Terms

Conditions

Postoperative Cognitive ComplicationsGlaucoma

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsCognitive DysfunctionCognition DisordersNeurocognitive DisordersMental DisordersOcular HypertensionEye Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
dr, assoc. prof.

Study Record Dates

First Submitted

June 21, 2021

First Posted

June 29, 2021

Study Start

September 1, 2021

Primary Completion

July 1, 2022

Study Completion

October 1, 2022

Last Updated

April 5, 2022

Record last verified: 2022-04

Data Sharing

IPD Sharing
Will not share

Locations